Condition: Endometriosis · Adenomyosis · Chronic Pelvic Inflammatory Disease · Sponsor: Staci Gruber, Ph.D.
Despite recent increases in both medical and recreational cannabis use in the United States and globally, little research has been conducted to determine the potential applications for womens health. A variety of medical cannabis and hemp-derived products on the marketplace claim to hold efficacy for many womens health-related conditions, including gynecologic pain. This 7-day study of individuals living with endometriosis, adenomyosis, or chronic pelvic inflammatory disease (PID), will identify specific targets and mechanisms underlying the potential impact of a hemp-derived, full-spectrum, high-CBD product in individuals with gynecologic pain.
This description comes directly from the study's public registry record.
Staci Gruber, PhD · 617-855-2762 · gruber@mclean.harvard.edu
Rosie Smith, M.S. · 617-855-2908 · rsmith@mclean.harvard.edu
Always discuss trial participation with your own doctor first.
| McLean Hospital | Belmont, Massachusetts, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07728695